Periodic Reporting for period 1 - ScanZ (Point of care medical device enabling patient self-assessment for acne diagnosis support.)
Periodo di rendicontazione: 2015-02-01 al 2015-05-31
In the Healthcare industry, easy to use handheld imaging device will become vital in order to ensure a sustainable and efficient health system in both a time and cost effective manner. The project’s main proponent, mySkin d.o.o,. aims to significantly contribute in creating innovative and sustainable principles in the Healthcare market, by improving the quality of life for acne sufferers and working conditions for medical professionals. The overall objective of ScanZ project is to move the technology from its readiness level 7 to 9, making the device clinically and commercially qualified for the market.
During the first medical trial at ORS Hospital Belgrade, mySkin obtained significant positive feedback from patients and medical professionals; and whilst scouting the dermatology clinics for holding medical trials during the PH2 project ScanZ has received strong interest from dermatology clinics across Europe as well as positive reviews from TechCrunch, CNET, NY Daily News, and the BBC.
During the first medical trial at ORS Hospital Belgrade, mySkin obtained significant positive feedback from patients and medical professionals; and whilst scouting the dermatology clinics for holding medical trials during the PH2 project ScanZ has received strong interest from dermatology clinics across Europe as well as positive reviews from TechCrunch, CNET, NY Daily News, and the BBC.
During the Feasibility assessment mySkin d.o.o. in partnership with ORS Hospital ran in-clinical tests confirming that ScanZ reduces assessment time up to 67% and visit time by up to 44%. The in-clinical test had shown that the device increases the throughput of the clinical with quantified measurements, giving better insight into each lesion changes and enabling physicians to have a consistent diagnostic quality. Post visit, the ScanZ platform introduces an objective element in monitoring lesions between visits.
The conducted (e/tele)-interviews with dermatologists have shown that there is a high demand for the ScanZ device. Prominent acne researchers have been looking or trying to develop such a device since 2005. Now that digital medical devices have become more recently available and popular, ScanZ is an ideal solution for implementation into their clinical staff and patient processes. The key criteria of selecting an appropriate device for the dermatologists was having a simple, easy to use device, that saves times, is affordable, and most importantly quantify acne and skin lesions.
Thanks to the Feasibility study, mySkin has decided to change the strategy by first focusing on the MD device, and then after understanding the clinical use-cases and patient flow, focus on the consumer edition (CE) of ScanZ. It would be the most efficient way to medicallyvalidate and certify the device and test both users experience and to become internationally recognized.
mySkin has achieved the business feasibility objectives defined in the PH1 proposal, by securing 4 hospitals (3 outside Serbia) for the clinical trials, obtaining interests of the EMDDA, conducting the comprehensive and market barriers analysis, as well as preparing the IP and marketing strategy and 5 years financial projection.
The conducted (e/tele)-interviews with dermatologists have shown that there is a high demand for the ScanZ device. Prominent acne researchers have been looking or trying to develop such a device since 2005. Now that digital medical devices have become more recently available and popular, ScanZ is an ideal solution for implementation into their clinical staff and patient processes. The key criteria of selecting an appropriate device for the dermatologists was having a simple, easy to use device, that saves times, is affordable, and most importantly quantify acne and skin lesions.
Thanks to the Feasibility study, mySkin has decided to change the strategy by first focusing on the MD device, and then after understanding the clinical use-cases and patient flow, focus on the consumer edition (CE) of ScanZ. It would be the most efficient way to medicallyvalidate and certify the device and test both users experience and to become internationally recognized.
mySkin has achieved the business feasibility objectives defined in the PH1 proposal, by securing 4 hospitals (3 outside Serbia) for the clinical trials, obtaining interests of the EMDDA, conducting the comprehensive and market barriers analysis, as well as preparing the IP and marketing strategy and 5 years financial projection.
The expected outcome of the project is to start the full commercialization of the MD version of ScanZ device at the end of PH2 as a reliable innovation medical validated, CE certified and IP protected. In simple words, to introduce to the Healthcare market the skin-imaging point of care device that will improve clinical decisions on the diagnosis and the most appropriate treatment, and therefore will lead to better overall health outcomes both in Europe and globally, while contributing to the sustainability of the health care system by reducing healthcare centres and doctors waiting times by transferring patient assessment to nurses.